Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) shares traded up 6.3% during trading on Wednesday . The company traded as high as $11.91 and last traded at $11.68. 41,461 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 3,210,973 shares. The stock had previously closed at $10.99.
Athira Pharma Stock Performance
The business’s 50-day moving average price is $6.96 and its 200 day moving average price is $5.67. The company has a market cap of $46.07 million, a P/E ratio of -1.21 and a beta of 2.79.
Institutional Trading of Athira Pharma
Hedge funds have recently modified their holdings of the stock. Focus Partners Wealth acquired a new stake in shares of Athira Pharma during the 3rd quarter worth about $35,000. Jane Street Group LLC acquired a new stake in shares of Athira Pharma during the 4th quarter worth about $100,000. Renaissance Technologies LLC lifted its stake in shares of Athira Pharma by 44.7% during the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after buying an additional 23,223 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Athira Pharma during the 4th quarter worth about $969,000. Finally, Millennium Management LLC acquired a new stake in shares of Athira Pharma during the 4th quarter worth about $2,456,000. Institutional investors and hedge funds own 57.12% of the company’s stock.
About Athira Pharma
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
Recommended Stories
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
